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Objectives This study sought to evaluate the characteristics, therapies, and outcomes of patients
with chronic kidney disease (CKD) presenting with non–ST-segment elevation myocardial infarction
(NSTEMI) and managed with percutaneous coronary intervention (PCI). This speciﬁc population has
not been evaluated previously.
Background Among patients with acute coronary syndrome, the presence of renal dysfunction is
associated with an increased risk of death and major bleeding.
Methods We examined data on 40,074 NSTEMI patients managed with PCI who were captured by
the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) registry. Patients were
divided according to baseline renal function in 4 groups: no CKD and CKD stages 3, 4, and 5.
Results Overall, 31.1% (n  12,045) of patients with NSTEMI undergoing PCI had CKD. Compared with pa-
tients with normal renal function, CKD patients managed with PCI had signiﬁcantly more history of myocardial
infarction, heart failure, and more 3-vessel coronary artery disease. They received fewer antithrombotic thera-
pies but were treated more frequently with bivalirudin. In addition, they had signiﬁcantly higher rates of in-
hospital mortality and major bleeding. CKD stage 4 was associated with the highest risk of adverse events
relative to no CKD. The multivariable adjusted odds ratios of in-hospital mortality for CKD stages 3, 4, and 5
relative to no CKD were 2.0, 2.8, and 2.6, respectively (global p value 0.0001), and the analogous adjusted
dds ratios of major bleeding were 1.5, 2.8, and 1.8, respectively (global p value 0.0001).
onclusions CKD patients presenting with NSTEMI and managed with PCI have more comorbidities and
eceive guideline-recommended therapies less frequently than do patients without CKD. CKD is strongly asso-
iated with in-hospital mortality and bleeding in NSTEMI patients undergoing PCI. (J Am Coll Cardiol Intv
011;4:1002–8) © 2011 by the American College of Cardiology Foundation
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1003Among patients with acute coronary syndromes (ACS), the
presence of renal dysfunction is associated with an increased
risk of death and major bleeding (1–9). Registry data
suggest that 14.5% to 42.9% of patients with non–ST-
segment elevation myocardial infarction (NSTEMI) have
moderate to severe chronic kidney disease (CKD) (2,3).
See page 1009
Despite the high prevalence of CKD, large randomized
trials that have addressed the benefit of an invasive strategy
in ACS have excluded patients with advanced CKD
(10,11). Subgroup analyses of these trials suggested a benefit
of an invasive strategy in patients with mild CKD (12), but
data assessing the interaction between CKD, outcomes, and
the use of an invasive strategy, particularly percutaneous
coronary intervention (PCI), is lacking. Although several
retrospective analyses have suggested an increased risk of
death and cardiac events in patients with CKD undergoing
PCI as compared to patients with normal renal function
(13,14), or in patients with CKD presenting with ACS
(1–9), they have not specifically studied ACS population
with CKD undergoing PCI.
Therefore, the aim of our study is to evaluate the baseline
characteristics, treatment patterns, and in-hospital outcomes of
patients with various stages of CKD presenting with
NSTEMI who are managed with PCI. We focused specifically
on patients who underwent PCI, a more homogeneous and
potentially healthier population than the general NSTEMI
population, and to examine the impact of CKD stage on
medication use and outcomes within this select population.
Methods
Patient population. The NCDR (National Cardiovascular
ata Registry)–ACTION-GWTG (Acute Coronary
reatment and Intervention Outcomes Network–Get With
he Guidelines) registry is an ongoing national database of
STEMI and ST-segment elevation myocardial infarction
STEMI) that began enrolling patients January 1, 2007.
he population for this study was derived from the 162,361
atients enrolled in the ACTION-GWTG registry from
anuary 1, 2007, to December 31, 2009, at 397 ACTION-
WTG hospitals. Patients were included in the registry if
hey had acute ischemic symptoms, positive cardiac bio-
arkers, and were admitted within 24 h of these symptoms.
atients within the ACTION-GWTG registry were in-
luded in this analysis if they had NSTEMI and underwent
n invasive strategy with subsequent PCI. Patients were
neligible for this analysis if they presented with STEMI
n 63,816), did not undergo cardiac catheterization or the
atheterization status was missing (n  24,899), were not
ound to have significant coronary artery disease (CAD) on
atheterization (n  6,387), or had significant CAD but anderwent coronary artery bypass grafting (n  10,288) or
o revascularization (n  16,067), were admitted to facili-
ies with no cardiac catheterization capability or were
ransferred in from facilities with no cardiac catheterization
apability (n  247), or if data for serum creatinine was
issing (n  583). Thus, the overall sample for our analysis
onsisted of 40,074 patients.
Glomerular filtration rate (GFR) was estimated via the
odification of Diet in Renal Disease equation. Stage 3
KD is defined as GFR between 30 and 59 ml/min/1.73 m2,
stage 4 CKD is defined as GFR between 15 and 29
ml/min/1.73 m2, and stage 5 CKD as GFR15 ml/min/1.73 m2
or dialysis therapy. Patients were divided based on baseline
renal function in 4 groups: 1) no CKD or CKD stage 1
or 2 (referred to as “no CKD” for the purpose of this
study); 2) CKD stage 3; 3)
CKD stage 4; and 4) CKD
stage 5.
Outcome deﬁnitions. The pri-
mary outcome was the short-
term in-hospital death. More-
over, we examined rates of major
bleeding. Major bleeding was
defined as an absolute hemoglo-
bin drop of 4 g/dl (baseline to
nadir), intracranial hemorrhage,
documented or suspected retro-
peritoneal bleed, any red cell
blood transfusion with a baseline
hemoglobin 9 g/dl, or any red
cell transfusion with a baseline
hemoglobin 9 g/dl and a sus-
pected bleeding event. Bleeding
in coronary artery bypass graft
patients was included as a bleed
only if it occurred before surgery.
Bleeding during or after surgery
was not included in the bleeding
definition.
Statistical analysis. Baseline demographics, clinical charac-
eristics, in-hospital treatments, and outcomes are shown
cross baseline CKD groups and p-trend values are re-
orted. Continuous variables are reported as medians and
5th and 75th percentiles and categorical variables are
eported as percentages. The p values are based on chi-
quare rank-based group means score statistics for all
ategorical variables and on chi-square 1° of freedom rank
orrelation statistics for all continuous or ordinal variables.
Logistic generalized estimating equations modeling was
sed to estimate the adjusted associations of CKD stages
ith outcomes. Variables used for in-hospital mortality
djustment were from the validated ACTION-GWTG
n-hospital mortality model (15): age, prior peripheral
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CAD  coronary artery
disease
CI  confidence interval
CKD  chronic kidney
disease
GFR  glomerular filtration
rate
HF  heart failure
NSTEMI  non–ST-segment
elevation myocardial
infarction
OR  odds ratios
PCI  percutaneous
coronary intervention
SBP  systolic blood
pressure
STEMI  ST-segment
elevation myocardial
infarctionrterial disease, systolic blood pressure (SBP) on presenta-
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1004tion, heart rate on presentation, heart failure (HF) or shock
on admission (HF only, shock only, or HF with shock, vs.
none), electrocardiographic findings (STEMI, ST-segment
depression, or transient ST-segment elevation vs. no ST-
segment changes), initial serum creatinine, and initial tro-
ponin ratio. Variables used for major bleeding adjustment
were from the validated ACTION-GWTG in-hospital
major bleeding model (16): age, female sex, diabetes, prior
peripheral arterial disease, home warfarin use, body weight, heart
rate on presentation, SBP on presentation (130 mm Hg, 130 to
60 mm Hg, and 160 mm Hg), HF on presentation (HF
nly, shock only or HF with shock, vs. none), electrocar-
iographic findings (STEMI, ST-segment changes vs. no
T-segment changes), initial serum creatinine, and baseline
emoglobin 12 g/dl (vs. 12 g/dl). STEMI and initial
erum creatinine were dropped from both models because
TEMI patients were excluded from this analysis and CKD
s a function of serum creatinine. Adjusted associations for
Table 1. Baseline Characteristics by CKD Stage
Variable
GFR >60 ml/min/1.73 m2
(n  28,029)
Demographics
Age, yrs 59 (51, 68)
Male 73.0
Race
White 85.5
Black 8.1
Hispanic 3.8
Other 2.6
Medical history
Hypertension 65.3
Diabetes mellitus 24.7
BMI, kg/m2 29.1 (25.8, 33.3)
Current smoking 42.8
Dyslipidemia 59.0
Prior MI 22.1
Prior PCI 24.0
Prior CABG 13.2
Prior heart failure 5.0
Prior stroke 4.3
History of PAD 6.0
Clinical features on presentation
Heart failure on presentation 6.8
Shock on presentation 0.6
Heart rate on presentation, beats/min 78 (68, 91)
SBP on presentation, mm Hg 148 (130, 167)
Baseline laboratory values
Estimated GFR, ml/min/1.73 m2* 81.4 (71.3, 94.7)
Hemoglobin, g/dl 14.4 (13.3, 15.4)
Troponin ratio,  ULN† 1.9 (0.45, 9.8)
Values are median (25th, 75th percentiles) or %. *GFR was estimated in nondialysis patients. †Trop
BMI  body mass index; CABG  coronary artery bypass grafting; CKD  chronic kidney diseaspercutaneous coronary intervention; SBP systolic blood pressure; ULN upper limit of normal.utcomes were displayed as odds ratios (ORs) (95% confi-
ence intervals [CIs]) and a global comparison p value was
alculated and reported. All analyses were performed using
AS software (version 9.2, SAS Institute, Cary, North
arolina).
esults
Study sample characteristics. Overall, 40,074 patients with
NSTEMI undergoing PCI were included; the peak tro-
ponin median was 30.4 times the upper limit of normal
(Online Table 1). Of those patients, 28,029 patients
(69.9%) had no CKD on presentation, 10,168 patients
(25.4%) had CKD stage 3, 930 patients (2.3%) had CKD
stage 4, and 947 patients (2.4%) had CKD stage 5, of which
790 patients were on chronic dialysis. With progressively
more advanced CKD, patients were more likely to have a
history of diabetes mellitus, prior heart failure, prior myo-
KD Stage 3
n  10,168)
CKD Stage 4
(n  930)
CKD Stage 5
(n  947)
p Value
for Trend
72 (64, 80) 74 (65, 81) 65 (57, 74) 0.0001
55.7 43.9 57.0 0.0001
0.0001
89.7 85.2 65.1
5.6 7.5 23.4
2.5 3.7 5.2
2.2 3.7 5.9
83.8 91.5 91.0 0.0001
39.9 62.4 70.1 0.0001
8.7 (25.4, 33.0) 28.7 (25.3, 33.4) 28.2 (24.6, 32.7) 0.0001
21.1 16.0 18.2 0.0001
68.8 72.7 69.0 0.0001
31.5 40.3 40.4 0.0001
33.6 39.7 44.6 0.0001
25.8 32.8 28.4 0.0001
15.4 33.3 37.1 0.0001
10.2 14.3 18.3 0.0001
14.6 23.4 31.7 0.0001
19.9 36.7 35.3 0.0001
2.2 4.7 3.1 0.0001
81 (69, 96) 84 (70, 97) 88 (76, 102) 0.0001
46 (126, 167) 141 (117, 165) 146 (121, 172) 0.0001
0.0 (42.6, 55.6) 25.7 (22.1, 28.1) 11.0 (8.3, 13.6)† 0.0001
3.4 (12.1, 14.6) 11.8 (10.7, 13.0) 12.0 (10.7, 13.3) 0.0001
1.8 (0.44, 9.8) 2.7 (0.70, 16.9) 2.9 (0.71, 14.0) 0.0011
tio initial troponin value/local laboratory troponin ULN.
 glomerular filtration rate; MI  myocardial infarction; PAD  peripheral arterial disease; PCI C
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1005cardial infarction, prior coronary revascularization, and pe-
ripheral arterial disease. As compared to patients with no
CKD, patients with CKD were more likely to have HF and
shock on presentation (Table 1).
In-hospital medications. After accounting for patient-level
ontraindications to individual medication classes, the early
se of antiplatelet and anticoagulant therapies was lower
mong patients with CKD. Only bivalirudin was used more
requently in patients with progressively more advanced CKD,
ncluding CKD stage 5. In addition, the use of approved ACS
herapies (statin and beta-blockers) was lower among patients
ith worse CKD (Table 2). The use of angiotensin-converting
nzyme inhibitors and/or angiotensin-receptor blockers was
owest among patients with CKD stage 4.
Angiographic ﬁndings. Patients with progressively more
dvanced CKD had more 3-vessel CAD and more left main
isease than did patients with no CKD (Table 3). Patients
ith CKD stage 4 had the highest prevalence of 3-vessel
AD.
In-hospital outcomes. Patients with various stages of CKD
ad higher rates of in-hospital mortality and major bleeding
han did patients with no CKD (Table 4). Notably, patients
ith CKD stage 4 had the highest rates of these adverse
Table 2. In-Hospital Medications* by CKD Stage
GFR >60 ml/min/1.73 m
(n  28,029)
Aspirin† 98.4
Clopidogrel† 79.6
Beta-blocker† 93.0
ACE-I and/or ARB† 51.4
Aldosterone receptor blocker† 1.3
Statin† 66.3
Any anticoagulant‡ 97.0
UFH‡ 67.0
LMWH‡ 36.9
Bivalirudin‡ 28.5
GP IIb/IIa antagonist‡ 60.4
Values are %. *Among patients without listed contraindications. †
hospitalization rather than within 24 h.
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiote
low-molecular weight heparin; UFH unfractionated heparin; other a
Table 3. Angiographic Findings by CKD Stage
Finding
GFR >60 ml/min/1.73 m2
(n  28,029)
1-vessel CAD 40.5
2-vessel CAD 34.7
3-vessel CAD 24.8
LAD stenosis 50% 66.4
Left main stenosis 50% 4.3
Values are %.CAD coronary artery disease; LAD left anterior descending artery; othen-hospital clinical events, with strikingly worse outcomes
han patients with CKD stage 5. The association of CKD
tages 3, 4, and 5 with increased risks of death and major
leeding relative to no CKD remained significant after
djustment for baseline characteristics using the multivari-
ble models (Table 4).
iscussion
Overall, 30.1% of patients with NSTEMI undergoing PCI
in this real-world registry had CKD. This is lower than the
prevalence of CKD among all NSTEMI patients enrolled
in the ACTION registry (overall prevalence of CKD:
42.9%) (3) and is probably explained by the fact that an
invasive strategy, particularly PCI, is less frequently used in
patients with CKD. Patients with CKD undergoing PCI
had more extensive CAD than patients without CKD, with
a 3-vessel CAD prevalence of 35% to 41% and left main
disease prevalence of 10%. In addition, CKD patients
undergoing PCI had significantly more comorbidities than
did patients without CKD, and the present study docu-
mented lower use of antithrombotic therapies and cardio-
protective medications among CKD patients. Thus, there
KD Stage 3
n  10,168)
CKD Stage 4
(n  930)
CKD Stage 5
(n  947)
p Value
for Trend
97.6 96.9 95.1 0.0001
73.3 66.4 65.6 0.0001
92.1 90.1 90.1 0.0001
51.9 38.2 46.6 0.04
2.3 2.2 1.6 0.0001
62.8 58.0 58.1 0.0001
96.1 94.9 94.3 0.0001
64.7 69.6 69.8 0.02
37.1 33.2 22.2 0.0006
32.7 32.1 35.0 0.0001
47.4 35.2 25.9 0.0001
tered within 24 h of presentation. ‡Recorded as any time during
eptor blocker; GP IIb/IIIa  glycoprotein IIb/IIIa inhibitor; LMWH 
tions as in Table 1.
Stage 3
10,168)
CKD Stage 4
(n  930)
CKD Stage 5
(n  947)
p Value
for Trend
30.1 23.4 25.1 0.0001
34.6 34.0 34.3 0.7350
35.3 42.6 40.6 0.0001
72.7 74.6 73.4 0.0001
9.1 13.7 11.1 0.00012 C
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1006seems to be a paradigm on the management of CKD
patients, where the highest-risk patients receive less
guideline-recommended measures, even when those pa-
tients are determined to be “healthy” enough to undergo
PCI procedures. This study is unique in that all patients
underwent PCI, yet there were significant disparities in the
concomitant use of evidence-based medications by CKD
stage.
The rates of adverse events were markedly higher in
patients with CKD as compared to patients without CKD.
This has been suggested by other registry data (1,17).
otably, patients with CKD stage 4 had a higher rate of
ortality and major bleeding as compared to CKD stages 3
r 5. This finding has not been described previously in this
atient population, and although noteworthy, it should be
nterpreted carefully. CKD stages 4 and 5 subgroups con-
isted of fewer patients than other subgroups in this analysis,
hich precludes us from drawing definitive conclusions
bout this result. Also, patients with CKD stage 4 in this
tudy were older than patients with CKD stage 5. In fact,
fter risk adjustment for multiple covariates that included
lder age of patients with CKD stage 4, the mortality OR of
atients with CKD stage 4, when compared with patients
ith no CKD, was similar to that of CKD stage 5. By
ontrast, several factors may contribute to better outcomes
n patients with CKD stage 5. It has been previously shown
hat patients with CKD stages 3 and 4 are 5 to 10 more
likely to die than they are to reach CKD stage 5 or
hemodialysis (18,19). As survivors of earlier stages of CKD,
patients with CKD stage 5 may thus represent a selection
bias. Furthermore, as compared to CKD stage 4 patients,
contrast-induced nephropathy may be less consequential in
CKD stage 5 patients who are already receiving dialysis,
which is the case of most patients with CKD stage 5 in this
study. In addition, dialysis improves the hemostatic defect
associated with advanced CKD, which may explain the
lower bleeding risk associated with CKD stage 5 (20).
Although CKD was associated with an increased mortal-
Table 4. Crude Rates and Multivariable Adjusted OR
by CKD Stage
GFR >60 ml/min/1.73 m
(n  28,029)
Death 0.6 (171)
Death adjusted * 1.0 (reference)
Major bleeding 5.5 (1,557)
Major bleeding adjusted† 1.0 (reference)
Values are % (n) or OR (95% CI). *Multivariable model for death adjust
on admission (HF only, shock only, or HF with shock, vs. none), hear
changes vs. no ST-segment changes). †Multivariable model for majo
disease, body weight, home warfarin use, SBP on presentation (SBP 
presentation, HF on presentation (HF only, shock only or HF with shoc
(ST-segment changes vs. no ST-segment changes).
CI confidence interval; ECG electrocardiogram; HF heart failuity risk in patients with NSTEMI undergoing PCI in ourstudy, this result neither opposes nor favors the performance
of PCI in this population. In fact, our reported mortality
rates are lower than those reported for the overall CKD
population with NSTEMI in the ACTION registry (the
mortality rates for no CKD, CKD stages 3a, 3b, 4, and 5
were 1.8%, 4.8%, 8.6%, 13.4%, and 12.4%, respectively) (3).
This may be related to the selection bias, wherein only the
healthier-perceived patients, those with less extensive co-
morbidities, or those with more favorable anatomy undergo
PCI as has been described previously (21), but it may also be
related to the more aggressive revascularization therapy in
these patients.
There are several potential explanations for the increased
risk of adverse outcomes across all CKD categories under-
going PCI. Platelet dysfunction related to CKD and dosing
errors of antithrombotic agents are factors that increase
bleeding risk among CKD patients and contribute to
increased mortality (22). In fact, excess dosing was shown to
be common among patients presenting with ACS, particu-
larly if they also had CKD, and was a major contributor to
major bleeding events and subsequent mortality (22). By
contrast, CKD patients have more extensive atherosclerosis
and more comorbidities including history of CAD, HF,
peripheral arterial disease, and anemia, which partly explain
their prognosis. In addition, the lower usage of proven
medical therapies may have played a role in worsening
outcomes. Furthermore, contrast-induced nephropathy oc-
curs more frequently in patients with CKD and is strongly
associated with mortality (23–26). However, because mor-
tality of the overall CKD population is high regardless of
invasive management, the isolated impact of contrast-
induced nephropathy on outcomes needs to be further
investigated.
The increased use of bivalirudin in patients with CKD
stages 4 and 5 is noteworthy. Even though bivalirudin was
associated with a lower bleeding risk than unfractionated
heparin and low-molecular-weight heparin in patients with-
out CKD as well as in patients with CKD stage 3 in the
n-Hospital Mortality and Major Bleeding
Stage 3
(n  10,168)
Stage 4
(n  930)
Stage 5
(n  947)
2.8 (284) 6.1 (57) 3.9 (37)
2.0 (1.6–2.5) 2.8 (2.0–4.1) 2.6 (1.7–4.1)
12.8 (1,300) 30.2 (281) 22.3 (211)
1.5 (1.4–1.6) 2.8 (2.4–3.3) 1.8 (1.5–2.2)
ge, prior peripheral arterial disease, SBP on presentation, HF or shock
n presentation, initial troponin ratio, and ECG findings (ST-segment
ing adjusted for: age, female sex, diabetes, prior peripheral arterial
m Hg, SBP 130 to 160 mm Hg, and SBP 160 mm Hg), heart rate on
ne), baseline hemoglobin12 g/dl (vs. 12 g/dl), and ECG findings
 odds ratio; other abbreviations as in Table 1.s for I
2
ed for: a
t rate o
r bleed
130 m
k, vs. noACUITY (Acute Catheterization and Urgent Intervention
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1007Triage Strategy) trial (27), this trial excluded patients with
CKD stages 4 and 5. Similarly, other large trials that
addressed bivalirudin therapy excluded patients with creat-
inine 4 mg/dl (28,29). Thus, the safety of bivalirudin in
patients with advanced CKD is not well established and the
dosage adjustment of the infusion is unclear, particularly as
bivalirudin is renally cleared and its half-life is significantly
increased in advanced CKD.
Study strengths and limitations. The major strength of this
study is the use of a large real-world multicenter registry.
However, certain limitations are notable. Being a retrospec-
tive registry analysis, there is an inherent selection bias,
under-reporting bias, and confounding related to unmea-
sured variables. We selected NSTEMI patients who under-
went PCI, an inherently healthier population than the
overall NSTEMI population; thus, our outcome data may
not apply to all patients with NSTEMI and CKD and
neither oppose nor favor the performance of PCI in these
patients. Moreover, we only evaluated short-term in-
hospital outcomes, but previous evidence suggests that these
poor outcomes are likely seen over the long-term follow-up
as well (1,2,6–8). The relatively small number of patients
with CKD stages 4 and 5 precludes definite conclusions
about outcomes in these subgroups.
Conclusions
CKD patients presenting with NSTEMI and managed with
PCI have more comorbidities than patients without CKD
have and are less frequently treated with the recommended
ACS therapies. CKD is strongly associated with in-hospital
mortality and bleeding events in patients undergoing PCI;
CKD stage 4, in particular, is associated with the highest
mortality and most adverse bleeding outcomes. Further
research is needed to elucidate the role of aggressive
revascularization strategies in improving outcomes of CKD
patients and their potential risk.
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